Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study

Antoinette J. Wozniak, John J. Crowley, Stanley P. Balcerzak, Geoffrey R. Weiss, C. Harris Spiridonidis, Laurence H. Baker, Kathy S. Albain, Karen Kelly, Sar A. Taylor, David R. Gandara, Robert B. Livingston

Research output: Contribution to journalArticle

500 Scopus citations

Abstract

Purpose: Cisplatin has played a major role in the treatment of non- small-cell lung cancer (NSCLC). This randomized trial was performed by the Southwest Oncology Group (SWOG) to determine whether the combination of vinorelbine and cisplatin has any advantage with regard to response rate, survival, and time to treatment failure over single-agent cisplatin in the treatment of patients with advanced NSCLC . Methods: Between October 1993 and April 1995, 432 patients with advanced stage NSCLC were randomized to receive arm I (cisplatin 100 mg/m2 every 4 weeks) or arm II (cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly). All patients were chemotherapy-naive, had performance status (PS) 0 or 1, and had adequate hematologic, renal, and hepatic function. Results: Four hundred fifteen patients were eligible and assessable. On arm I (cisplatin), there was a 12% partial response rate. Arm II (cisplatin and vinorelbine) had a 26% response rate (2% complete responses and 24% partial responses, P = .0002). There was a statistically significant advantage with regard to progression-free survival (median, 2 v 4 months; P = .0001) and overall survival (median, 6 v 8 months; P = .0018) for the cisplatin and vinorelbine arm. One-year survival was 20% for cisplatin alone and 36% for the combination arm. There was more hematologic toxicity on arm II of the study (81% grades 3 and 4 granulocytopenia v 5% on arm I). Other toxicities, such as renal insufficiency, ototoxicity, and nausea and vomiting, and neuropathy were similar. Conclusion: The results of this study indicate that the combination of cisplatin and vinorelbine is a superior treatment when compared with single-agent cisplatin in the treatment of advanced NSCLC. Cisplatin and vinorelbine is the new standard for SWOG against which new therapies will be evaluated.

Original languageEnglish (US)
Pages (from-to)2459-2465
Number of pages7
JournalJournal of Clinical Oncology
Volume16
Issue number7
StatePublished - Jul 1998

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this

    Wozniak, A. J., Crowley, J. J., Balcerzak, S. P., Weiss, G. R., Spiridonidis, C. H., Baker, L. H., Albain, K. S., Kelly, K., Taylor, S. A., Gandara, D. R., & Livingston, R. B. (1998). Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. Journal of Clinical Oncology, 16(7), 2459-2465.